Pull to refresh
Logo
Daily Brief
Following
Why Ranks Sign Up
MG

Menarini Group

Pharmaceutical company

Appears in 1 story

Stories

FDA approves AbbVie's Decnupaz for ultra-rare BPDCN blood cancer

New Capabilities

Elzonris sponsor; presenting new tagraxofusp combination data at ASCO 2026

The FDA approved AbbVie's Decnupaz on May 27 for blastic plasmacytoid dendritic cell neoplasm, an aggressive blood cancer. It strikes an estimated few hundred Americans a year. It's the second drug ever approved for the disease and the first doctors can start in an outpatient clinic.

Updated May 28